Last reviewed · How we verify
Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer
The goal of this clinical research study is to find the highest tolerable dose of the combination of bevacizumab (Avastin) and temsirolimus (Torisel) that can be given with 1 of 3 other study drugs --carboplatin (Paraplatin), paclitaxel (Taxol), or sorafenib (Nexavar). The safety of these drug combinations will also be studied.
Details
| Lead sponsor | M.D. Anderson Cancer Center |
|---|---|
| Phase | PHASE1 |
| Status | ACTIVE_NOT_RECRUITING |
| Enrolment | 278 |
| Start date | Thu Aug 19 2010 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu Apr 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Advanced Cancer
Interventions
- Temsirolimus
- Bevacizumab
- Paclitaxel
- Sorafenib
- Carboplatin
Countries
United States